Skip to main content
. 2017 Jan 10;8(8):12953–12967. doi: 10.18632/oncotarget.14588

Figure 7. Cerdulatinib inhibits the activity of NF-κB pathway.

Figure 7

A. Phosphorylation of IκBα following cerdulatinib treatment. CLL cells were stimulated with either plate-bound αIgM alone or combined IL4+CD40L+plate-bound αIgM stimuli, and treated with 2 µM cerdulatnib for 24 hrs. Whole Cell lysates were immunoblotted for p-IκBα and GAPDH as the loading control. Four representative blots are shown. B. Reduction in p-IκBα is dose-dependent on cerdulatinib. CLL cells were stimulated with combined IL4+CD40L+plate-bound αIgM stimuli. C. Cerdulatinib decreased nuclear P65. Nuclear extracts were prepared from each sample and were immunoblotted for P65 and lamin B, a nuclear marker. D. DNA binding activity of NFκB subunit p50. Nuclear extracts were prepared from each sample. P50 activity was measured by ELISA plates coated with oligonucleotides containing the NF-kB consensus sequence (59-GGGACTTTCC-39). Concentration of p50 was determined by comparing samples with a standard curve of purified p50 protein, results represent mean±SE of 6 CLL samples. ****P < 0.001.